Shopping Cart
- Remove All
Your shopping cart is currently empty
SARS-COV-2 Spike S1 Protein (D614G, His & Avi)
Catalog No. TMPK-00436
The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.
SARS-COV-2 Spike S1 Protein (D614G, His & Avi)
Catalog No. TMPK-00436
The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 μg | $511 | 7-10 days | |
| 500 μg | $2,040 | 7-10 days | |
| 1 mg | $3,410 | 7-10 days |
Bulk & Custom
Add to Cart
Resource Download
Product Information
| Biological Activity | Immobilized SARS-CoV-2 S1 (D614G) , His Tag at 2μg/ml (100μl/Well) on plate.Dose response curve for Human ACE2, hFc Tag with the EC50 of 23.7ng/ml determined by ELISA. |
| Description | The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct. |
| Species | SARS-CoV-2 |
| Expression System | HEK293 Cells |
| Tag | C-His-Avi |
| Accession Number | A0A6G7K2L4 |
| Synonyms | Spike,S1 protein,Spike protein S1,S1 protein,S glycoprotein Subunit1 |
| Construction | Gln14-Arg683(D614G) |
| Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Molecular Weight | 77.9 kDa (predicted). Due to glycosylation, the protein migrates to 110-120 kDa based on Tris-Bis PAGE result. |
| Endotoxin | < 1 EU/μg by the LAL method. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
| Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. |
| Research Background | The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct. |
Dose Conversion
You can also refer to dose conversion for different animals. More
Calculator
Tech Support
Please read the User Guide of Recombinant Proteins for more specific information.
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.